311 related articles for article (PubMed ID: 12859615)
1. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?
Gauthier Y; Cario Andre M; Taïeb A
Pigment Cell Res; 2003 Aug; 16(4):322-32. PubMed ID: 12859615
[TBL] [Abstract][Full Text] [Related]
2. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces.
Kumar R; Parsad D
Indian J Dermatol Venereol Leprol; 2012; 78(1):19-23. PubMed ID: 22199056
[TBL] [Abstract][Full Text] [Related]
3. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis.
Cario-André M; Pain C; Gauthier Y; Taïeb A
Pigment Cell Res; 2007 Oct; 20(5):385-93. PubMed ID: 17850512
[TBL] [Abstract][Full Text] [Related]
4. Melanocyte Adhesion and Apoptosis in Vitiligo: Linking Puzzle Blocks.
Srivastava N; Gupta S; Parsad D
Curr Mol Med; 2023; 23(8):709-711. PubMed ID: 35726816
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo: where do we stand?
Ortonne JP; Bose SK
Pigment Cell Res; 1993 Mar; 6(2):61-72. PubMed ID: 8321867
[TBL] [Abstract][Full Text] [Related]
6. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected?
Namazi MR
Pigment Cell Res; 2007 Oct; 20(5):360-3. PubMed ID: 17850509
[TBL] [Abstract][Full Text] [Related]
7. New insights into immune mechanisms of vitiligo.
Boniface K; Taïeb A; Seneschal J
G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
[TBL] [Abstract][Full Text] [Related]
8. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo.
Wagner RY; Luciani F; Cario-André M; Rubod A; Petit V; Benzekri L; Ezzedine K; Lepreux S; Steingrimsson E; Taieb A; Gauthier Y; Larue L; Delmas V
J Invest Dermatol; 2015 Jul; 135(7):1810-1819. PubMed ID: 25634357
[TBL] [Abstract][Full Text] [Related]
9. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
[TBL] [Abstract][Full Text] [Related]
10. Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study.
Benzekri L; Hmamouchi I; Gauthier Y
Br J Dermatol; 2015 Feb; 172(2):331-6. PubMed ID: 24902987
[TBL] [Abstract][Full Text] [Related]
11. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo.
Kumar R; Parsad D; Kanwar AJ
Br J Dermatol; 2011 Jan; 164(1):187-91. PubMed ID: 21175561
[TBL] [Abstract][Full Text] [Related]
12. Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors.
Goldstein NB; Koster MI; Hoaglin LG; Spoelstra NS; Kechris KJ; Robinson SE; Robinson WA; Roop DR; Norris DA; Birlea SA
J Invest Dermatol; 2015 Aug; 135(8):2068-2076. PubMed ID: 25822579
[TBL] [Abstract][Full Text] [Related]
13. The genetics of generalized vitiligo.
Spritz RA
Curr Dir Autoimmun; 2008; 10():244-57. PubMed ID: 18460890
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenesis of vitiligo.
Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
[TBL] [Abstract][Full Text] [Related]
15. Review of the etiopathomechanism of vitiligo: a convergence theory.
Le Poole IC; Das PK; van den Wijngaard RM; Bos JD; Westerhof W
Exp Dermatol; 1993 Aug; 2(4):145-53. PubMed ID: 8162332
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
17. Surgical procedures and innovative approaches for vitiligo regenerative treatment and melanocytorrhagy.
Kawakami T
J Dermatol; 2022 Apr; 49(4):391-401. PubMed ID: 35178747
[TBL] [Abstract][Full Text] [Related]
18. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
19. Evidence for an autoimmune pathogenesis of vitiligo.
Ongenae K; Van Geel N; Naeyaert JM
Pigment Cell Res; 2003 Apr; 16(2):90-100. PubMed ID: 12622785
[TBL] [Abstract][Full Text] [Related]
20. Melanocyte destruction and repigmentation in vitiligo: a model for nerve cell damage and regrowth.
Yu HS
J Biomed Sci; 2002; 9(6 Pt 2):564-73. PubMed ID: 12432222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
